Streetbeat News

Products Services

PRTG

Portage Biotech reported a net loss of $75.4 million for FY24, an improvement from the $104.7 million loss last year. The company is discontinuing its iNKT clinical trial for PORT-2 and pausing patient enrollment in other trials due to funding requirements. Portage is exploring strategic alternatives, including partnerships, sales, mergers, restructurings, or further financing.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:15 am

EXAS

Exact Sciences shared new modeling data on the projected impact of the Cologuard test on patients, health care professionals, and the U.S. health care system since its FDA approval 10 years ago.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:10 am

QURE

uniQure has dosed the first patient in its Phase I/IIa clinical trial of AMT-191, a gene therapy for Fabry disease. This marks a significant milestone in the development of treatments for this rare genetic disorder.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:09 am

VERI

Veritone announced that its media and entertainment solutions are now available in the AWS Marketplace, allowing customers to find, test, buy, and deploy software that runs on Amazon Web Services.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:07 am

RNAZ

TransCode Therapeutics has announced the initiation of a Phase 1 study for its lead therapeutic candidate, TTX-MC138. This study marks a significant milestone for the company as it advances its clinical pipeline.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:06 am

CVAC

CureVac has advanced its cancer vaccine candidate CVGBM to Part B of its Phase 1 study in patients with resected glioblastoma. The first patient has been administered the dose-confirmation, and Part B is expected to include up to 20 patients to gather extended data on safety, tolerability, and immunogenicity.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:05 am

DIA

GLD

QQQ

SPY

USO

U.S. stock markets closed higher on August 14th, with the S&P 500 extending its winning streak to five sessions, supported by lower-than-expected inflation data. The Dow Jones Industrial Average and Nasdaq Composite also saw gains. Asian markets mostly rose, while European markets were mixed. Commodities like oil and gold saw price increases.

Portfolio Pulse from Akanksha Bakshi

August 15, 2024 | 10:54 am

TSLA

Tesla's average transaction price (ATP) has risen to $59,593, driven by the success of the high-end Cybertruck and price increases for the Model Y and Model 3. The Cybertruck, priced over $100,000, was the best-selling vehicle in the U.S. last month. Tesla's price adjustments have led to higher ATPs, despite previous price cuts to boost deliveries.

Portfolio Pulse from Anan Ashraf

August 15, 2024 | 10:52 am

HAE

Haemonetics announced the full market release of its Vascade MVP XL Mid-bore Venous Closure System, which is the latest addition to its Vascade portfolio. The system features collapsible disc technology and a proprietary resorbable collagen patch to promote rapid hemostasis.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 10:38 am

KALV

The European Medicines Agency has validated KalVista Pharmaceuticals' marketing application for Sebetralstat, a treatment for hereditary angioedema.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 10:35 am